Healthcare & Medical Devices Global On demand · 24-48h

Global Blood Filtering Device Market Strategic Research Report

Global Blood Filtering Device Market Strategic Research Repo…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Blood Filtering Device Market
$4682025
4.5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Red Blood Cell Filter, Whole Blood Filter, Platelet Filter

By Application: Medical Centre, Hospital, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Asahi Kasei Medical, Haemonetics, Fresenius, Macopharma, Shandong Zhongbaokang, Nanjing Shuangwei, Chengdu Shuanglu, Braile Biomedica, Nanjing Cellgene

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 87 pages
Market size 2025
$468
Million USD
Forecast CAGR
4.5%
2025-2032
Forecast 2032
$636.9
Projected
リージョン
5
Asia Pacific · Latin America · MEA · Europe · North America

概観

Scope of the Report

The global Blood Filtering Device market size is predicted to grow from US$ 468 million in 2025 to US$ 635 million in 2032; it is expected to grow at a CAGR of 4.5% from 2026 to 2032.

A blood filtering device is a medical device or consumable-based system used in clinical transfusion, blood component processing, extracorporeal circulation, blood purification, autotransfusion, and critical-care support. It typically consists of filtration membranes, filter cartridges, tubing, housings, connectors, pressure-monitoring components, flow-control modules, and a sterile closed pathway. Through mechanical retention, membrane separation, depth filtration, adsorption, or hollow-fiber exchange, it removes or separates clots, microaggregates, leukocytes, cellular debris, fat particles, air bubbles, inflammatory mediators, toxins, or metabolic waste from blood. Compared with a single blood filter, a blood filtering device places greater emphasis on integration with transfusion systems, heart-lung machines, ECMO, dialysis equipment, CRRT systems, or autologous blood salvage devices. It is a critical link among devices, consumables, treatment workflows, and blood-safety management. Because it directly contacts human blood, this product requires extremely high standards for biocompatibility, hemocompatibility, filtration efficiency, sealing performance, sterility assurance, and clinical operating safety.In 2025, global Blood Filtering Device production reached approximately 113.8 million units.The average gross profit margin of this product is 30%.

The core opportunity for the blood filtering device market comes from higher blood-safety standards, the development of critical-care medicine, wider adoption of extracorporeal circulation technologies, increasing demand for renal replacement therapy, and the upgrading of precision treatment capabilities in hospitals. As clinical demand rises for component transfusion, leukocyte control, intraoperative autologous blood salvage, ECMO support, cardiopulmonary bypass, continuous renal replacement therapy, and dialysis quality, blood filtering devices are evolving from traditional supporting components into system-level products that help ensure treatment safety, reduce complication risks, and improve workflow efficiency. For CEOs, marketing leaders, and investors, this sector is attractive because of rigid clinical demand, recurring consumable usage, device-installed-base-driven consumable lock-in, and high registration and quality-system barriers. High-end filtration membranes, closed consumable kits, intelligent pressure monitoring, low blood-cell-damage designs, and integrated device-consumable platforms will become important drivers of industry value upgrading.

The greatest challenge in this industry is the extremely high safety boundary of the product. Any material leaching, filtration failure, coagulation activation, hemolysis, residual air bubbles, or contamination risk may directly affect patient safety. A blood filtering device must not only achieve effective filtration, but also maintain appropriate flow resistance, stable flux, blood-cell integrity, and anticoagulation compatibility. This creates systematic requirements for membrane materials, structural design, fluid dynamics, surface modification, sterilization processes, and clean assembly. Regulators generally impose strict requirements on blood-contacting devices in terms of biocompatibility, hemocompatibility, sterility assurance, performance validation, and clinical evaluation, making validation cycles long and capital investment high for new entrants. At the same time, hospital procurement, reimbursement cost control, and domestic substitution may compress margins for mid- and low-end products, while high-end markets remain strongly occupied by international brands. Companies without core materials, quality traceability, system integration, and clinical application support will find it difficult to build stable competitiveness.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Blood Filtering Device market?

What factors are driving Blood Filtering Device market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Blood Filtering Device market opportunities vary by end market size?

How does Blood Filtering Device break out by Type, by Application?

This report presents a comprehensive overview of the global Blood Filtering Device market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Red Blood Cell Filter
  • Whole Blood Filter
  • Platelet Filter

Segment by Use Stage

  • Blood Collection Filters
  • Pre-storage Filters
  • Bedside Transfusion Filters
  • Other

Segment by Product Structure

  • Flat Membrane Filters
  • Pleated Membrane Filters
  • Depth Filters
  • Other

Segment by Application

  • Medical Centre
  • Hospital
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Blood Filtering Device market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Medical Centre, Hospital, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Blood Filtering Device Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 4.5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$468
2025
Forecast
$636.9
2032
CAGR
4.5%
2025–2032
リージョン
5
global
Key companies
Asahi Kasei MedicalHaemoneticsFreseniusMacopharmaShandong ZhongbaokangNanjing ShuangweiChengdu ShuangluBraile Biomedica
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Red Blood Cell FilterWhole Blood FilterPlatelet Filter
By Application
Medical CentreHospitalOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Red Blood Cell Filter
  • 3.1.3 Whole Blood Filter
  • 3.1.4 Platelet Filter
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Medical Centre
  • 4.1.3 Hospital
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Asahi Kasei Medical
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Haemonetics
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Fresenius
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Macopharma
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Shandong Zhongbaokang
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Nanjing Shuangwei
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Chengdu Shuanglu
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Braile Biomedica
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Nanjing Cellgene
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Blood Filtering Device market?
The global Blood Filtering Device market is estimated at US$ 468 million in 2025 (base year) and is projected to reach US$ 635 million by 2032.
What is the forecast CAGR for the Blood Filtering Device market?
The market is expected to grow at a CAGR of 4.5% from 2026 to 2032, expanding from US$ 468 million in 2025 to US$ 635 million in 2032, roughly 1.4 times its base-year value.
What is Blood Filtering Device?
A blood filtering device is a medical device or consumable-based system used in clinical transfusion, blood component processing, extracorporeal circulation, blood purification, autotransfusion, and critical-care support. It typically consists of filtration membranes, filter cartridges, tubing, housings, connectors, pressure-monitoring components, flow-control modules, and a sterile closed pathway.
How is the Blood Filtering Device market segmented by type?
By type, the market is segmented into Red Blood Cell Filter, Whole Blood Filter and Platelet Filter.
What are the key applications of Blood Filtering Device?
Key applications covered include Medical Centre, Hospital and Others.
Which companies are profiled in the Blood Filtering Device market report?
Key players profiled include Asahi Kasei Medical, Haemonetics, Fresenius, Macopharma, Shandong Zhongbaokang, Nanjing Shuangwei, Chengdu Shuanglu and Braile Biomedica, among 9 companies covered in total.
What geographies does the Blood Filtering Device market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Blood Filtering Device?
For CEOs, marketing leaders, and investors, this sector is attractive because of rigid clinical demand, recurring consumable usage, device-installed-base-driven consumable lock-in, and high registration and quality-system barriers.
What are the main risks and barriers in the Blood Filtering Device market?
The greatest challenge in this industry is the extremely high safety boundary of the product.
Who should buy the Blood Filtering Device market report?
The report is intended for manufacturers and solution providers, distributors and end users in Medical Centre, Hospital and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Blood Filtering Device market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.